The administration of pirfenidone modifies the expression of JMJD2B in a murine model of NASH

The administration of pirfenidone modifies the expression of JMJD2B in a murine model of NASH

Introduction and Objectives: This study aimed to evaluate how the administration of pirfenidone modifies the expression of JMJD2B in a murine model of NASH. Materials and methods: 4–5-week-old male C57BL/6J mice fed a high-fat diet for 16 weeks. Follow-up was done at 4, 8, 12 and 16 weeks. Serum glu...

Full description

Bibliographic Details
Main Authors:	JS Rodriguez Sanabria, J García Bañuelos, R Escutia Gutiérrez, CA Monraz Méndez, A Santos, J Armendáriz-Borunda, AS Sandoval Rodríguez
Format:	Article
Language:	English
Published:	Elsevier 2022-12-01
Series:	Annals of Hepatology
Online Access:	http://www.sciencedirect.com/science/article/pii/S166526812200196X

Similar Items

Moringa oleifera decreases biomarkers of oxidative stress in a murine NASH model
by: A Monraz-Méndez, et al.
Published: (2022-12-01)

Pirfenidone ameliorates MAFLD by improving insulin sensitivity and reducing epididymal fat
by: J. Gutiérrez-Cuevas, et al.
Published: (2022-12-01)

P- 25 ANTIOXIDANT EFFECT OF MORINGA OLEIFERA IN A MURINE MODEL OF NONALCOHOLIC STEATOHEPATITIS
by: Alejandra Monraz-Méndez, et al.
Published: (2023-03-01)

Pirfenidone Is an Agonistic Ligand for PPARα and Improves NASH by Activation of SIRT1/LKB1/pAMPK
by: Ana Sandoval‐Rodriguez, et al.
Published: (2020-03-01)

Pirfenidone decreases insulin, glucagon, leptin, plasminogen activator inhibitor 1, preventing nonalcoholic steatohepatitis and myocarditis in an obesity moldel
by: Daniel López-Cifuentes, et al.
Published: (2024-02-01)

Pirfenidone Protects from UVB-Induced Photodamage in Hairless Mice
by: Yocasta Martinez-Alvarado, et al.
Published: (2023-03-01)

Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases
by: Jorge Gutiérrez-Cuevas, et al.
Published: (2021-10-01)

Pirfenidone regulates antioxidant response via NRF2 in an experimental model of hepatocellular carcinoma
by: HC Monroy-Ramírez, et al.
Published: (2022-12-01)

P- 43 PIRFENIDONE PREVENTS NEOPLASTIC LESIONS DEVELOPMENT BY OXIDATIVE, FIBROGENIC, ANTIPROLIFERATIVE AND EPIGENETIC MECHANISMS REGULATION IN A MODEL OF CHEMICAL HEPATOCARCINOGENESIS
by: Hipólito Otoniel Miranda-Roblero, et al.
Published: (2023-03-01)

O-24 PIRFENIDONE PREVENTS NEOPLASTIC LESIONS DEVELOPMENT BY OXIDATIVE, FIBROGENIC, ANTIPROLIFERATIVE AND EPIGENETIC MECHANISMS REGULATION IN A MODEL OF CHEMICAL HEPATOCARCINOGENESIS
by: Hipólito Otoniel Miranda-Roblero, et al.
Published: (2023-03-01)

Dietary supplementation with methyl donors improves physiopathological conditions of NAFLD in a murine model
by: A Vazquez Esqueda, et al.
Published: (2022-12-01)

<i>Moringa oleifera</i> Improves MAFLD by Inducing Epigenetic Modifications
by: C. Alejandra Monraz-Méndez, et al.
Published: (2022-10-01)

Pirfenidone slows the development of fibrosis and malignant neoplasms by modulating inflammation in an experimental model of hepatocarcinoma.
by: Scarlet Arceo-Orozco, et al.
Published: (2024-02-01)

Liquid biopsy of patients with advanced liver fibrosis reveals the association of methylation in CpGs and miRNAs expression with the degree of severity
by: R De la Rosa-Bibiano, et al.
Published: (2022-12-01)

Hepatocarcinogenesis Prevention by Pirfenidone Is PPARγ Mediated and Involves Modification of Nuclear NF-kB p65/p50 Ratio
by: Jorge Antonio Silva-Gomez, et al.
Published: (2021-10-01)

Role of pirfenidone in the management of pulmonary fibrosis
by: Meyer KC, et al.
Published: (2017-04-01)

Epidemiologic, Genetic, Pathogenic, Metabolic, Epigenetic Aspects Involved in NASH-HCC: Current Therapeutic Strategies
by: Jorge Gutiérrez-Cuevas, et al.
Published: (2022-12-01)

Advances of Nanotechnology in the Diagnosis and Treatment of Hepatocellular Carcinoma
by: Rebeca Escutia-Gutiérrez, et al.
Published: (2023-10-01)

The gut microbiota and key parameters associated with MAFLD are modified by MEXMIX
by: R Rosas-Campos, et al.
Published: (2022-12-01)

Editorial: Community series - liver fibrosis and MAFLD: from molecular aspects to novel pharmacological strategies, volume II
by: Ana Sandoval-Rodriguez, et al.
Published: (2024-02-01)

Pirfenidone induces translocation of sirt1 to nucleus and deacetylation of histone 3 slows down the development of fibrosis and tumorigenicity in a experimental model of hepatocarcinoma.
by: Hugo C. Monroy-Ramírez, et al.
Published: (2024-02-01)

The Novel Protease Activities of JMJD5–JMJD6–JMJD7 and Arginine Methylation Activities of Arginine Methyltransferases Are Likely Coupled
by: Haolin Liu, et al.
Published: (2022-02-01)

Effect of methyl donor supplementation on gut microbiota and hepatic expression of key miRNAs in a murine model of MAFLD
by: Rebeca Rosas-Campos, et al.
Published: (2024-02-01)

Exploring the metabolic and molecular benefits of methyl donor supplementation in a model of metabolic and fatty liver disease
by: Angel Vazquez-Esqueda, et al.
Published: (2024-02-01)

Biochemical and biophysical studies on the Jumonji-C hydroxylases JMJD7 and JMJD4
by: Markolovic, S
Published: (2017)

Pirfenidone increases IL-10 and improves acute pancreatitis in multiple clinically relevant murine models
by: Ejas Palathingal Bava, et al.
Published: (2022-01-01)

Inhibition of Ureteral Stricture by Pirfenidone-Loaded Nanoparticle-Coated Ureteral Stents with Slow-Release Pirfenidone
by: Jiang Z, et al.
Published: (2022-12-01)

MexMix supplementation prevented MAFLD development by restoring microbiota-gut-liver axis in a mice model.
by: Rebeca Rosas-Campos, et al.
Published: (2024-02-01)

Mexican Ancestral Foods (<i>Theobroma cacao, Opuntia ficus indica, Persea americana</i> and <i>Phaseolus vulgaris)</i> Supplementation on Anthropometric, Lipid and Glycemic Control Variables in Obese Patients: A Systematic Review and Meta-Analysis
by: Rebeca Escutia-Gutiérrez, et al.
Published: (2023-03-01)

Cell Autophagy in NASH and NASH-Related Hepatocellular Carcinoma
by: Utibe-Abasi S. Udoh, et al.
Published: (2022-07-01)

Topical Pirfenidone-Loaded Liposomes Ophthalmic Formulation Reduces Haze Development after Corneal Alkali Burn in Mice
by: Carlos Daniel Diaz-Palomera, et al.
Published: (2022-01-01)

Methyl-group donor supplementation beneficial effects on metabolic, histological, and inflammatory parameters in a murine model of alcoholic steatohepatitis
by: Carolina Diaz-Canul, et al.
Published: (2024-02-01)

Pirfenidone and tendon healing: Comment
by: Hinpetch Daungsupawong, et al.
Published: (2024-01-01)

Effect of pirfenidone on tendon healing
by: Yasemin Aydinli, et al.
Published: (2023-01-01)

P- 77 EPIGENOME OF PATIENTS WITH LIVER FIBROSIS, WITH SUSTAINED VIRAL RESPONSE TO HCV IN LIVER BIOPSY AND LIQUID BIOPSY REVEALS THE ASSOCIATION OF DNA METHYLATION AND miRNA EXPRESSION WITH THE DEGREE OF SEVERITY
by: Ricardo De la Rosa-Bibiano, et al.
Published: (2023-03-01)

Inhibition of JMJD6 by 2-oxoglutarate mimics
by: Islam, MS, et al.
Published: (2021)

The Functions of the Demethylase JMJD3 in Cancer
by: Anna Sanchez, et al.
Published: (2021-01-01)

JMJD3 in the regulation of human diseases
by: Xiangxian Zhang, et al.
Published: (2019-11-01)

Role of JMJD6 in Breast Tumourigenesis.
by: Coralie Poulard, et al.
Published: (2015-01-01)

Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond
by: Alberto Aimo, et al.
Published: (2022-04-01)